CO5190710A1 - Antagonistas de un receptor de il-8 un receptor de il-8 - Google Patents
Antagonistas de un receptor de il-8 un receptor de il-8Info
- Publication number
- CO5190710A1 CO5190710A1 CO00044233A CO00044233A CO5190710A1 CO 5190710 A1 CO5190710 A1 CO 5190710A1 CO 00044233 A CO00044233 A CO 00044233A CO 00044233 A CO00044233 A CO 00044233A CO 5190710 A1 CO5190710 A1 CO 5190710A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cr8r8
- alkenyl
- optionally substituted
- heteroaryl
- Prior art date
Links
- 108090001007 Interleukin-8 Proteins 0.000 title 2
- 239000005557 antagonist Substances 0.000 title 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000003342 alkenyl group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 3
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 2
- 108010012236 Chemokines Proteins 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000000623 heterocyclic group Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229910052717 sulfur Chemical group 0.000 abstract 2
- 239000011593 sulfur Chemical group 0.000 abstract 2
- -1 (CR8R8) qS (O) tR4 Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 108010018976 Interleukin-8A Receptors Proteins 0.000 abstract 1
- 241000124008 Mammalia Species 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 241000700605 Viruses Species 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 125000005018 aryl alkenyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000004104 aryloxy group Chemical group 0.000 abstract 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 abstract 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 abstract 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 abstract 1
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 1
- 208000007565 gingivitis Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 150000002367 halogens Chemical group 0.000 abstract 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 abstract 1
- 208000006454 hepatitis Diseases 0.000 abstract 1
- 231100000283 hepatitis Toxicity 0.000 abstract 1
- 125000004447 heteroarylalkenyl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 125000005343 heterocyclic alkyl group Chemical group 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 230000000241 respiratory effect Effects 0.000 abstract 1
- 208000037803 restenosis Diseases 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 241001529453 unidentified herpesvirus Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
Abstract
Compuesto para tratar un estado de enfermedad mediado por quimioquina, seleccionado del grupo que consta de malaria, reestenosis, angiogénesis, aterosclerosis, osteoporosis, gingivitis, liberación de células tronco hematopoyéticas indeseadas, y enfermedades causadas por virus respiratorios, virus del herpes, y virus de la hepatitis, en el que la quimioquina se fija a un receptor de IL-8 a ó ß en un mamífero, dicho compuesto de fórmula:<EMI FILE="00044233_1" ID="1" IMF=JPEG >en la queX es oxígeno o azufre;R es cualquier resto funcional que tiene un hidrógeno ionizable y un pKa de 10 o menos;R1 se selecciona independientemente entre hidrógeno, halógeno, nitro, ciano, alquilo C1-10 sustituido con halo, alquilo C1-10, alquenilo C2-10, alcoxi C1-10, alcoxi C1-10 halosustituido, azido, (CR8R8)qS(O)tR4, hidroxi, hidroxi-alquilo C1-4, arilo, aril-alquilo C1-4, ariloxi, aril-alquil C1-4-oxi, heteroarilo, heteroaril-alquilo, heterocíclico, heterocíclico-alquilo C1-4, heteroaril-alquil C1-4-oxi, aril-alquenilo C2-10, heteroaril-alquenilo C2-10, heterocíclico-alquenilo C2-10, (CR8R8)qNR4R5 alquenil C2-10-C(O)-NR4R5, (CR8R8)qC(O)NR4R5, (CR8R8)qC(O)NR4R10, S(O)3H, S(O)3R8, (CR8R8)qC(O)R11, alquenil C2-10-C(O)R11, alquenil C2-10-C(O)OR11 (CR8R8)qC(O)OR12, (CR8R8)qOC(O)R11, (CR8R8)qNR4C(O)R11, (CR8R8)q-NHS(O)2R17, (CR8R8)qS(O)2NR4R5, o dos restos R1 juntos pueden formar O-(CH2)S-O- o un anillo insaturado de 5 a 6 miembros;q es 0, o un número entero que tiene un valor de 1 a 10;m es un número entero que tiene un valor de 1 a 3;t es 0, o un número entero que tiene un valor de 1 ó 2;s es un número entero que tiene un valor de 1 a 3;v es 0, o un número entero que tiene un valor de 1 a 4;R4 y R5 son independientemente hidrógeno, alquilo C1-4opcionalmente sustituido, arilo opcionalmente sustituido, aril-alquilo C1-4 opcionalmente sustituido,heteroarilo opcionalmente sustituido, heteroaril-alquilo C1-4 opcionalmente sustituido, heterocíclico o heterocíclico-alquilo C1-4, o R4 y R5 junto con el nitrógeno al que están unidos, forman un anillo de 5 a 7 miembros que opcionalmente puede comprender un heteroátomo adicional seleccionado entre oxígeno, nitrógeno y azufre;HET es un resto heteroarilo opcionalmente sustituido;R8 es hidrógeno o alquilo C1-4;R10 es alquil C1-10-C(O)2R8; ...
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13968099P | 1999-06-15 | 1999-06-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5190710A1 true CO5190710A1 (es) | 2002-08-29 |
Family
ID=22487818
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00044233A CO5190710A1 (es) | 1999-06-15 | 2000-06-14 | Antagonistas de un receptor de il-8 un receptor de il-8 |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1194143A4 (es) |
| JP (1) | JP2003501450A (es) |
| AU (1) | AU6051200A (es) |
| CO (1) | CO5190710A1 (es) |
| HK (1) | HK1044717A1 (es) |
| WO (1) | WO2000076457A2 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1608319A4 (en) | 2003-04-03 | 2007-02-28 | Univ California | IMPROVED HEMMER FOR SOLUBLE EPOXY HYDROLASE |
| EP1765311A4 (en) | 2004-03-16 | 2009-04-29 | Univ California | REDUCTION OF NEPHROPATHY WITH INHIBITORS OF SOLUBLE EPOXY HYDROLASE AND EPOXYEICOSANOIDS |
| AU2005295167B2 (en) | 2004-10-20 | 2012-05-10 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| EP2528604B1 (en) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4008326A (en) * | 1973-12-26 | 1977-02-15 | The Upjohn Company | Substituted ureas and thioureas and pharmaceutical compositions thereof |
| EP0809492A4 (en) * | 1995-02-17 | 2007-01-24 | Smithkline Beecham Corp | IL-8 RECEPTOR ANTAGONISTS |
| JP2000513359A (ja) * | 1996-06-27 | 2000-10-10 | スミスクライン・ビーチャム・コーポレイション | Ｉｌ―８受容体拮抗薬 |
-
2000
- 2000-06-14 CO CO00044233A patent/CO5190710A1/es unknown
- 2000-06-15 AU AU60512/00A patent/AU6051200A/en not_active Abandoned
- 2000-06-15 WO PCT/US2000/016500 patent/WO2000076457A2/en not_active Application Discontinuation
- 2000-06-15 JP JP2001502797A patent/JP2003501450A/ja not_active Withdrawn
- 2000-06-15 EP EP00946813A patent/EP1194143A4/en not_active Withdrawn
-
2002
- 2002-08-27 HK HK02106334.0A patent/HK1044717A1/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1194143A2 (en) | 2002-04-10 |
| WO2000076457A2 (en) | 2000-12-21 |
| WO2000076457A3 (en) | 2001-05-17 |
| AU6051200A (en) | 2001-01-02 |
| JP2003501450A (ja) | 2003-01-14 |
| EP1194143A4 (en) | 2004-02-04 |
| HK1044717A1 (zh) | 2002-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5200760A1 (es) | Antagonistas del receptor de la il-8 ceptor il-8 | |
| CO5280059A1 (es) | Derivados de 2-ox-1-pirrolidina, procewo para prepararlos y sus aplicaciones | |
| CY1109604T1 (el) | Αγωνιστες των βητα-2αδρενεργικων υποδοχεων | |
| CO5280070A1 (es) | Compuestos, composiciones farmaceuticas de indazol y metodos para mediar o inhibir la proliferacion celular | |
| DE60140127D1 (en) | Dihydroxypyrimidin-carbonsäuren als virale polymerase inhibitoren | |
| CO5261589A1 (es) | Compuestos heterociclicos, su produccion y su utilizacion | |
| ES2185338T3 (es) | Derivados de fumagilol y procedimientos para su fabricacion. | |
| EA200201259A1 (ru) | Производные бензимидазола, их получение и терапевтическое применение | |
| CO5031286A1 (es) | Compuestos de ciano guanadina como antagonistas de los receptores de il-8 y metodo de preparacion | |
| AR033803A1 (es) | Compuestos de dianilino escuarano, composiciones farmaceuticas que los comprenden, y el uso de los mismos en la fabricacion de medicamentos para tratar enfermedades mediadas por quimioquinas | |
| AR032398A1 (es) | Compuesto de escuaramida de sulfonamida, composicion farmaceutica que lo comprende y uso de dicho compuesto para preparar dicha composicion | |
| CO5190696A1 (es) | Antagonistas de los receptores il-8 | |
| DE69913958D1 (de) | Nichtkristalline feste dispergierende Zusammensetzung mit Cefuroximaxetil | |
| CO5190710A1 (es) | Antagonistas de un receptor de il-8 un receptor de il-8 | |
| CO5251405A1 (es) | 2-(3,5-bis-trifluorometil-fenil)-n-metil-n-(6-morfolin-4-il- 4-o-tolil-piridin-3-il)-isobutiramida | |
| AR037940A1 (es) | Compuestos antivirales de piridoquinoxalina | |
| AR008331A1 (es) | Compuestos antagonistas de un receptor de il-8, uso de los mismos para la fabricacion de medicamentos, procedimiento para su obtencion, composicionesfarmaceuticas que los contienen | |
| FR2798126B1 (fr) | Heteroaryloxypropanolamines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| CO5190712A1 (es) | Antagonistas de los receptores de la il-8 de los receptores de la il-8 | |
| CO5170514A1 (es) | Antagonistas de los receptores de la il-8 nistas del receptor de la il-8 | |
| CO5170528A1 (es) | Antagonistas de los receptores de la il-8 nistas del recpetor de la il-8 | |
| CO5271703A1 (es) | Compuestos quimicos | |
| CO5261594A1 (es) | Inhibidores de myt1 cinasa | |
| CO5190720A1 (es) | Antagonistas de los receptores de la il-8 gonistas de los receptores de il-8 | |
| AR036204A1 (es) | Proceso para la produccion de quinazolinas y compuestos utiles en dicho proceso |